Diverse strategies of analgesic adjustment are often, respectively, used to sustain analgesic efficiency for opioid-tolerant patients with different refractory factors of pain. In order to select effective analgesic adjustment strategy for hospice patient without knowing explicit causes of diminishing analgesic efficiency, a retrospective data of 743 patients among 3760 hospice patients were analyzed. The efficacy and adverse effects were not significantly different among analgesic adjustment strategies at each adjustment. Opioid duration was not associated with clinical characteristics. For opioid-tolerant hospice patients, the analgesic adjustment strategy can be selected for individual patient. After repeated analgesic adjustments, opioid tapering may also occur.
American Cancer Society. Cancer Facts and Figures 2008. Atlanta, GA: American Cancer Society; 2008.
2.
FerrellBConnorSRCordesA. The national agenda for quality palliative care: the National Consensus Project and the National Quality Forum. J Pain Symptom Manage. 2007;33(6):737–744.
3.
SlatkinNE. Opioid switching and rotation in primary care: implementation and clinical utility. Curr Med Res Opin. 2009;25(9):2133–2150.
4.
diDengYunxiangZhaoxinWuLingFuYunfengZhou. Sex differences in the impact of pain management among hospice patients. Chin J Pain Med. 2012;18(3):158–162.
5.
MercadanteSPortenoyRK. Opioid poorly-responsive cancer pain. Part 1: clinical considerations. J Pain Symptom Manage. 2001;21(2):144–150.
6.
JadadARCarrollDGlynnCJMooreRAMcQuayHJ. Morphine responsiveness of chronic pain: double-blind randomised crossover study with patient-controlled analgesia. Lancet. 1992;339(8806):1367–1371.
BohnLMGainetdinovRRLinFTLefkowitzRJCaronMG. Mu-opioid receptor desensitization by beta-arrestin-2 determines morphine tolerance but not dependence. Nature. 2000;408(6813):720–723.
9.
HanksGWConnoFChernyN. Morphine and alternative opioids in cancer pain: the EAPC recommendations. Br J Cancer. 2001;84(5):587–593.
10.
Garcia de ParedesMLdel Moral GonzalezFMartinez del PradoP. First evidence of oncologic neuropathic pain prevalence after screening 8615 cancer patients. Results of the On study. Ann Oncol. 2011;22(4):924–930.
11.
GilronIBaileyJMTuDHoldenRRWeaverDFHouldenRL. Morphine, gabapentin, or their combination for neuropathic pain. N Engl J Med. 2005;352(13):1324–1334.
12.
LiXiao-meiLiuDan-qWuHang-yuYangChunYangLi. Controlled-release oxycodone alone or combined with gabapentin for management of malignant neuropathic pain. Chin J Cancer Res. 2010;22(1):80–86.
13.
KhanMIWalshDBrito-DellanN. Opioid and adjuvant analgesics: compared and contrasted. Am J Hosp Palliati Care. 2011;28(5):378–383.
14.
MercadanteSPortenoyRK. Opioid poorly-responsive cancer pain. Part 3. Clinical strategies to improve opioid responsiveness. J Pain Symptom Manage. 2001;21(4):338–354.
15.
DaleOMoksnesKKaasaS. European Palliative Care Research Collaborative pain guidelines: opioid switching to improve analgesia or reduce side effects. A systematic review. Palliat Med. 2011;25(5):494–503.
16.
SjogrenPJensenNHJensenTS. Disappearance of morphine-induced hyperalgesia after discontinuing or substituting morphine with other opioid agonists. Pain. 1994;59(2):313–316.
17.
KnotkovaHFinePGPortenoyRK. Opioid rotation: the science and the limitations of the equianalgesic dose table. J Pain Symptom Manage. 2009;38(3):426–439.
18.
BallantyneJCMaoJ. Opioid therapy for chronic pain. N Engl J Med. 2003;349(20):1943–1953.
19.
JuliusDBasbaumAI. Molecular mechanisms of nociception. Nature. 2001;413(6852):203–210.
20.
DietisNGuerriniRCaloGSalvadoriSRowbothamDJLambertDG. Simultaneous targeting of multiple opioid receptors: a strategy to improve side-effect profile. Br J Anaesth. 2009;103(1):38–49.
21.
MaoJSungBJiRRLimG. Chronic morphine induces downregulation of spinal glutamate transporters: implications in morphine tolerance and abnormal pain sensitivity. J Neurosci. 2002;22(18):8312–8323.
22.
LaulinJPMaurettePCorcuffJBRivatCChauvinMSimonnetG. The role of ketamine in preventing fentanyl-induced hyperalgesia and subsequent acute morphine tolerance. Anesth Analg. 2002;94(5):1263–1269.
23.
HwangSSChangVTKasimisB. Cancer breakthrough pain characteristics and responses to treatment at a VA medical center. Pain. 2003;101(1-2):55–64.
24.
MaoJPriceDDMayerDJ. Experimental mononeuropathy reduces the antinociceptive effects of morphine: implications for common intracellular mechanisms involved in morphine tolerance and neuropathic pain. Pain. 1995;61(3):353–364.
25.
FainsingerRLFairchildANekolaichukCLawlorPLoweSHansonJ. Is pain intensity a predictor of the complexity of cancer pain management?J Clin Oncol. 2009;27(4):585–590.
26.
CohenSPChristoPJWangS. The effect of opioid dose and treatment duration on the perception of a painful standardized clinical stimulus. Reg Anesth Pain Med. 2008;33(3):199–206.
TheNCCNAdult Cancer Pain Clinical Practice Guidelines in Oncology vNCCN, Inc. http://www.nccn.org. Accessed Apri 27, 2011.
29.
BrueraESchoellerTWenkR. A prospective multicenter assessment of the Edmonton staging system for cancer pain. J Pain Symptom Manage. 1995;10(5):348–355.
30.
KaasaSLogeJH. Quality of life in palliative care: principles and practice. Palliat Med. 2003;17(1):11–20.
31.
World Health Organization. Cancer Pain Relief. Geneva, Switzerland: World Health Organization; 1996:3–37.
32.
ReddyAYennurajalingamSPulivarthiK. Frequency, outcome, and predictors of success within 6 weeks of an opioid rotation among outpatients with cancer receiving strong opioids. Oncologist. 2013;18(2):212–220.
33.
GregorianRSJrGasikAKwongWJVoellerSKavanaghS. Importance of side effects in opioid treatment: a trade-off analysis with patients and physicians. J Pain. 2010;11(11):1095–1108.
34.
LaurettiGRLimaICReisMPPradoWAPereiraNL. Oral ketamine and transdermal nitroglycerin as analgesic adjuvants to oral morphine therapy for cancer pain management. Anesthesiology. 1999;90(6):1528–1533.
35.
KannanTRSaxenaABhatnagarSBarryA. Oral ketamine as an adjuvant to oral morphine for neuropathic pain in cancer patients. J Pain Symptom Manage. 2002;23(1):60–65.
